Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 17 (11 Pt 1), 1056-8

A Randomized, Double-Blind, Placebo-Controlled Trial of Casein Protein Hydrolysate (C12 Peptide) in Human Essential Hypertension

Affiliations
Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Casein Protein Hydrolysate (C12 Peptide) in Human Essential Hypertension

Raymond R Townsend et al. Am J Hypertens.

Abstract

Background: Many patients seek complementary medicine treatments like neutraceuticals for common conditions such as hypertension.

Methods: We conducted a placebo-controlled prospective randomized crossover study in 10 hypertensive subjects to determine whether a single dose of a hydrolysate of bovine milk protein (designated C12 peptide; low and high dose), either alone or combined with alginic acid (low and high dose), reduced daytime blood pressure (BP), as determined by ambulatory BP monitoring.

Results: Within the five treatment regimens a significant reduction of 9.2 +/- 3.2 mm Hg in systolic BP at h 6 compared with h 2 occurred on the higher dose of alginic acid (1754 mg) combined with C12 (P = .02). The C12 peptide with the higher dose of alginic acid also showed a significant reduction of 6.0 +/- 2.0 mm Hg in diastolic BP at h 6 compared with h 2 (P = .015).

Conclusions: These preliminary data are encouraging and deserve testing in a larger and longer treatment trial.

Comment in

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

Publication types

Feedback